These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9784085)

  • 1. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.
    Glick SD; Maisonneuve IM; Visker KE; Fritz KA; Bandarage UK; Kuehne ME
    Psychopharmacology (Berl); 1998 Oct; 139(3):274-80. PubMed ID: 9784085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibogaine and the dopaminergic response to nicotine.
    Maisonneuve IM; Mann GL; Deibel CR; Glick SD
    Psychopharmacology (Berl); 1997 Feb; 129(3):249-56. PubMed ID: 9084063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.
    Maisonneuve IM; Glick SD
    Eur J Pharmacol; 1999 Oct; 383(1):15-21. PubMed ID: 10556676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens.
    Taraschenko OD; Shulan JM; Maisonneuve IM; Glick SD
    Synapse; 2007 Jul; 61(7):547-60. PubMed ID: 17447255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.
    Glick SD; Kuehne ME; Maisonneuve IM; Bandarage UK; Molinari HH
    Brain Res; 1996 May; 719(1-2):29-35. PubMed ID: 8782860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel medications for drug addiction. The legacy of an African shrub.
    Glick SD; Maisonneuve IM
    Ann N Y Acad Sci; 2000; 909():88-103. PubMed ID: 10911925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
    Glick SD; Maisonneuve IM; Szumlinski KK
    Ann N Y Acad Sci; 2000 Sep; 914():369-86. PubMed ID: 11085336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine.
    Eggan BL; McCallum SE
    Behav Brain Res; 2016 Jul; 307():186-93. PubMed ID: 27059333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats.
    McCallum SE; Taraschenko OD; Hathaway ER; Vincent MY; Glick SD
    Psychopharmacology (Berl); 2011 May; 215(2):247-56. PubMed ID: 21210086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
    Maisonneuve IM; Glick SD
    Pharmacol Biochem Behav; 2003 Jun; 75(3):607-18. PubMed ID: 12895678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats.
    Pearl SM; Maisonneuve IM; Glick SD
    Neuropharmacology; 1996; 35(12):1779-84. PubMed ID: 9076757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catharanthine Modulates Mesolimbic Dopamine Transmission and Nicotine Psychomotor Effects via Inhibition of α6-Nicotinic Receptors and Dopamine Transporters.
    Williams BM; Steed ND; Woolley JT; Moedl AA; Nelson CA; Jones GC; Burris MD; Arias HR; Kim OH; Jang EY; Hone AJ; McIntosh JM; Yorgason JT; Steffensen SC
    ACS Chem Neurosci; 2024 May; 15(9):1738-1754. PubMed ID: 38613458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.
    Benwell ME; Holtom PE; Moran RJ; Balfour DJ
    Br J Pharmacol; 1996 Feb; 117(4):743-9. PubMed ID: 8646423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of antiaddictive actions of ibogaine.
    Glick SD; Maisonneuve IS
    Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment.
    Szumlinski KK; Maisonneuve IM; Glick SD
    Brain Res; 2000 May; 864(1):13-23. PubMed ID: 10793182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
    Wei D; Maisonneuve IM; Kuehne ME; Glick SD
    Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.
    Rezvani AH; Cauley MC; Slade S; Wells C; Glick S; Rose JE; Levin ED
    Pharmacol Biochem Behav; 2016; 150-151():153-157. PubMed ID: 27984095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18-MC reduces methamphetamine and nicotine self-administration in rats.
    Glick SD; Maisonneuve IM; Dickinson HA
    Neuroreport; 2000 Jun; 11(9):2013-5. PubMed ID: 10884062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine.
    Szumlinski KK; Maisonneuve IM; Glick SD
    Eur J Pharmacol; 2000 Jun; 398(2):259-62. PubMed ID: 10854838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iboga interactions with psychomotor stimulants: panacea in the paradox?
    Szumlinski KK; Maisonneuve IM; Glick SD
    Toxicon; 2001 Jan; 39(1):75-86. PubMed ID: 10936624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.